Navigation Links
Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets
Date:1/4/2011

NEW YORK, Jan. 4, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

http://www.reportlinker.com/p0357279/Emerging-Opportunities-in-Biosimilar-and-Biobetter-Drugs-Markets.html

Executive SummaryThe biosimilar and biobetter drugs market has started to position itself in a grand manner following a series of changes in regulatory framework in many countries. The biosimilar market segment represents a host of opportunities to the generics manufacturers to enter in a market, which is largely driven by commands premium prices and unmet needs. Backed by this feature, the market is continuing to outperform the global pharmaceutical market. "Emerging Opportunities in Biosimilar and Biobetter Drugs Markets" provides a detailed overview and a succinct, but deep-dive analysis on the biosimilar and biobetter drugs segments. The report discusses various exclusive features of biobetter drugs and studies their importance in meeting the future demand. It also highlights various emerging trends in the market and relates these with the future market growth.

The key objective of this report is to identify and probe into the emerging opportunities in the biobetter and biosimilar drugs market. It also tries to estimate the opportunities in various biological drugs segments including monoclonal antibodies, Erythropoietin and insulin, thus giving a complete idea about the market dynamics to the target audience of this report.

The report Emerging Opportunities in Biosimilar and Biobetter Drugs Markets also includes information on the key players in the industry and their product portfolio. This will enable the target audience of this report in understanding the contemporary industry scenario. Besides, the report gives complete information on various products whose patents are on the verge of expiration and thus, it is offering huge opportunities for generics manufacturers. Some of the key findings of report are given below:

  • The clause of "12 Year Exclusivity" for biologics in the US healthcare reform bill is going to have a long term impact on the growth of biosimilar drugs market
  • The increasing application of monoclonal antibodies in the cancer treatment is going to boost the demand of biosimilar and biobetter drugs in this market segment

  • Delivery TimeThree Business days

    To order this report:: Emerging Opportunities in Biosimilar and Biobetter Drugs Markets

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
    '/>"/>

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
    2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
    3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
    4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
    5. Reportlinker Adds Nanomedicine Report
    6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
    7. Reportlinker Adds Nanoporous Materials Report
    8. Reportlinker Adds Membrane Bioreactors Report
    9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
    10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
    11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
    (Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
    (Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
    (Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
    Breaking Biology Technology:
    (Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
    (Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
    (Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
    Breaking Biology News(10 mins):